Cells that are about to die send a signal to an executioner protein, but sometimes, those cells can fight back and regenerate ...

Scientists are unraveling the role of senescent cells in a common form of epilepsy, and it could point to new treatments.

A recent study links chemotherapy to impaired ovarian function and fertility through oxidative damage to ovarian follicles.

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...

(Yicai) Jan. 13 -- Shares of RemeGen surged by their daily trading limit in Shanghai after the Chinese drugmaker granted US ...

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...

A ₹3.5 crore Madhya Pradesh-funded study on cow dung and urine as cancer treatment raises questions over scientific validity, ...

The interferon regulatory factor (IRF) family of transcription factors, pivotal for initiating antiviral type I interferon ...

Combination therapy of botensilimab (BOT) plus balstilimab (BAL) was approved Monday as an updated national treatment protocol for patients with certain ovarian cancers and soft tissue sarcomas (STS) ...

The deal is the second Chinese oncology pact in as many weeks for AbbVie, which also committed $175 million for a ...